BRPI0413565A - análogos de quinazolina como inibidores de receptor de tirosina quinase - Google Patents

análogos de quinazolina como inibidores de receptor de tirosina quinase

Info

Publication number
BRPI0413565A
BRPI0413565A BRPI0413565-2A BRPI0413565A BRPI0413565A BR PI0413565 A BRPI0413565 A BR PI0413565A BR PI0413565 A BRPI0413565 A BR PI0413565A BR PI0413565 A BRPI0413565 A BR PI0413565A
Authority
BR
Brazil
Prior art keywords
kinase receptor
receptor inhibitors
tyrosine kinase
quinazoline analogs
analogs
Prior art date
Application number
BRPI0413565-2A
Other languages
English (en)
Inventor
Eli Wallace
George Topalov
Joseph Lyssikatos
Alexandre Buckmelter
Qian Zhao
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/642,440 external-priority patent/US7501427B2/en
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of BRPI0413565A publication Critical patent/BRPI0413565A/pt
Publication of BRPI0413565B1 publication Critical patent/BRPI0413565B1/pt
Publication of BRPI0413565B8 publication Critical patent/BRPI0413565B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Materials Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Structural Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

"ANáLOGOS DE QUINAZOLINA COMO INIBIDORES DE RECEPTOR DE TIROSINA QUINASE". Essa invenção fornece análogos de quinazolina de Fórmula (I): onde A é ligado a pelo menos um dos carbonos na posição 5, 6, 7 ou 8 do anel bicíclico, e o anel é substituído por até dois grupos R¬ 3¬ independentes. A invenção também inclui métodos de uso de compostos de Fórmula (I) como inibidores de receptor de tirosina quinase tipo I e para o tratamento de doenças hiperproliferativas como câncer.
BRPI0413565A 2003-08-14 2004-08-10 análogos de quinazolina como inibidores de receptor de erbb2, seu uso e sua composição farmacêutica BRPI0413565B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/642.440 2003-08-14
US10/642,440 US7501427B2 (en) 2003-08-14 2003-08-14 Quinazoline analogs as receptor tyrosine kinase inhibitors
US55171804P 2004-03-10 2004-03-10
US60/551.718 2004-03-10
PCT/US2004/026235 WO2005016346A1 (en) 2003-08-14 2004-08-10 Quinazoline analogs as receptor tyrosine kinase inhibitors

Publications (3)

Publication Number Publication Date
BRPI0413565A true BRPI0413565A (pt) 2006-10-17
BRPI0413565B1 BRPI0413565B1 (pt) 2019-10-01
BRPI0413565B8 BRPI0413565B8 (pt) 2021-05-25

Family

ID=34198338

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413565A BRPI0413565B8 (pt) 2003-08-14 2004-08-10 análogos de quinazolina como inibidores de receptor de erbb2, seu uso e sua composição farmacêutica

Country Status (24)

Country Link
US (2) US7452895B2 (pt)
EP (1) EP1660090B1 (pt)
JP (1) JP4828421B2 (pt)
KR (2) KR101028952B1 (pt)
CN (3) CN102432552B (pt)
AR (1) AR045378A1 (pt)
AU (1) AU2004264937B2 (pt)
BR (1) BRPI0413565B8 (pt)
CA (1) CA2535614C (pt)
CL (1) CL2004002066A1 (pt)
CY (1) CY1113992T1 (pt)
DK (1) DK1660090T3 (pt)
ES (1) ES2399427T3 (pt)
HK (1) HK1085400A1 (pt)
IL (1) IL173593A (pt)
IS (1) IS8288A (pt)
MX (1) MXPA06001767A (pt)
NO (1) NO336275B1 (pt)
NZ (1) NZ545459A (pt)
PL (1) PL1660090T3 (pt)
PT (1) PT1660090E (pt)
RU (1) RU2350605C2 (pt)
TW (1) TWI353982B (pt)
WO (1) WO2005016346A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7488823B2 (en) * 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
ES2399427T3 (es) 2003-08-14 2013-04-01 Array Biopharma, Inc. Análogos de quinazolina como inhibidores de los receptores de la tirosina-quinasa
PT2090575E (pt) 2005-11-15 2011-06-06 Array Biopharma Inc Inibidores de erbb
WO2013056183A1 (en) 2011-10-14 2013-04-18 Array Biopharma Inc. Polymorphs of arry-380, a selective herb2 inhibitor and pharmaceutical compositions contianing them
RS56608B1 (sr) 2011-10-14 2018-02-28 Array Biopharma Inc Čvrsta disperzija
ES2855142T3 (es) 2012-03-23 2021-09-23 Array Biopharma Inc Compuestos para la utilización en el tratamiento de las metástasis cerebrales en un paciente con cáncer de mama ErbB2+
ES2882031T3 (es) * 2015-09-04 2021-12-01 Aslan Pharmaceuticals Pte Ltd Una terapia combinada que comprende varlitinib y un agente antineoplásico
WO2017184086A1 (en) * 2016-04-21 2017-10-26 Aslan Pharmaceuticals Pte. Ltd. Method of treating liver cancer
GB201611580D0 (en) * 2016-07-01 2016-08-17 Aslan Pharmaceuticals Pte Ltd Method
CN106349231A (zh) * 2016-08-09 2017-01-25 浙江医药高等专科学校 一类含卤代噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂
CN106317040A (zh) * 2016-08-09 2017-01-11 浙江医药高等专科学校 含噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂、制备方法及用途
CN106279135A (zh) * 2016-08-09 2017-01-04 浙江医药高等专科学校 一种噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂
CN106317039A (zh) * 2016-08-09 2017-01-11 浙江医药高等专科学校 一种含噻吩磺酰胺结构的乙氧苯并喹唑啉类酪氨酸激酶抑制剂、制备方法及用途
CN106349230A (zh) * 2016-08-09 2017-01-25 浙江医药高等专科学校 一种含硝基噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂及用途
WO2018038684A1 (en) 2016-08-26 2018-03-01 Agency For Science, Technology And Research Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof
WO2018160138A1 (en) 2017-03-02 2018-09-07 Aslan Pharmaceuticals Pte Ltd Dhodh inhibitor for treating haematological cancer
WO2018201016A1 (en) 2017-04-28 2018-11-01 Cascadian Therapeutics, Inc. Treatment of her2 positive cancers
WO2018222135A1 (en) 2017-06-02 2018-12-06 Aslan Pharmaceuticals Pte Ltd Cancer therapy
WO2018222134A1 (en) 2017-06-02 2018-12-06 Aslan Pharmaceuticals Pte Ltd Cancer therapy
CA3099776A1 (en) 2018-09-18 2020-03-26 Suzhou Zanrong Pharma Limited Quinazoline derivatives as antitumor agents
AU2019359036A1 (en) 2018-10-09 2021-06-03 Aslan Pharmaceuticals Pte Ltd Malonate salt of varlitinib
CN111499622B (zh) * 2019-07-08 2023-06-06 山东省科学院菏泽分院 一种治疗胆管癌的药物的制备方法
TW202214641A (zh) 2020-06-30 2022-04-16 美商艾瑞生藥股份有限公司 Ｈｅｒ２突變抑制劑
WO2023185793A1 (zh) * 2022-03-28 2023-10-05 江苏恒瑞医药股份有限公司 含氮杂环类化合物、其制备方法及其在医药上的应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2583774A (en) 1948-04-30 1952-01-29 Merck & Co Inc Vitamin b6 derivatives
BE795970A (fr) 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
CA1340821C (en) 1988-10-06 1999-11-16 Nobuyuki Fukazawa Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
US5204348A (en) * 1988-10-06 1993-04-20 Mitsui Toatsu Chemicals Inc. Heterocyclic compounds and anticancer-drug potentiaters conaining them as effective components
US5502187A (en) 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (pt) 1994-11-12 1997-12-01 Zeneca Ltd
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
SK285141B6 (sk) 1996-02-13 2006-07-07 Astrazeneca Uk Limited Použitie chinazolínového derivátu, chinazolínový derivát, spôsob jeho prípravy a farmaceutická kompozícia, ktorá ho obsahuje
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
DK0892789T4 (da) 1996-04-12 2010-04-06 Warner Lambert Co Irreversible inhibitorer af tyrosin kinaser
ID19609A (id) 1996-07-13 1998-07-23 Glaxo Group Ltd Senyawa-senyawa heterosiklik
US6225318B1 (en) 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
IL135636A0 (en) 1997-11-11 2001-05-20 Pfizer Prod Inc Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
JP2002505288A (ja) 1998-03-02 2002-02-19 コセンシス，インコーポレイテッド 置換キナゾリンおよびアナログならびにそれらの使用
US6017922A (en) 1998-05-18 2000-01-25 U.S. Bioscience, Inc. Thermally stable trimetrexates and processes for producing the same
EA003786B1 (ru) 1998-11-19 2003-10-30 Варнер Ламберт Компани N-[4-(3-хлор-4-фторфениламино)-7-(3-морфолин-4-илпропокси)хиназолин-6-ил]акриламид - необратимый ингибитор тирозинкиназ
BR9916904A (pt) 1999-01-13 2001-10-30 Warner Lambert Co Benzo heterociclos e seu uso como inibidores demek
HU228964B1 (en) * 1999-02-10 2013-07-29 Astrazeneca Ab Quinazoline derivatives as angiogenesis inhibitors, process for their preparation and medicaments containing them
GB9922171D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
AU763242B2 (en) 1999-09-21 2003-07-17 Astrazeneca Ab Quinazoline compounds and pharmaceutical compositions containing them
MXPA02007929A (es) 2000-02-17 2003-02-10 Squibb Bristol Myers Co Ligandos derivados de anilina para el receptor de la tiroides.
PT1287001E (pt) * 2000-06-06 2004-12-31 Pfizer Prod Inc Derivados de tiofeno uteis como agentes anticancerigenos
MXPA02012870A (es) * 2000-06-22 2003-05-14 Pfizer Prod Inc Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal.
TW200914443A (en) * 2000-06-30 2009-04-01 Glaxo Group Ltd Process for preparing substituted quinazolinyl furanaldehyde
WO2003015778A1 (en) 2001-08-17 2003-02-27 Merck & Co., Inc. Tyrosine kinase inhibitors
AU2002361577A1 (en) 2001-10-30 2003-05-12 Merck And Co., Inc. Tyrosine kinase inhibitors
WO2003040108A1 (en) * 2001-11-03 2003-05-15 Astrazeneca Ab Quinazoline derivatives as antitumor agents
CA2471577C (en) * 2001-12-24 2011-08-02 Astrazeneca Ab Chemical compounds
US7488823B2 (en) 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
JP2006515871A (ja) 2003-01-23 2006-06-08 ティー．ケイ． シグナル リミテッド 上皮増殖因子受容体チロシンキナーゼの不可逆阻害剤ならびにその使用
PE20040945A1 (es) 2003-02-05 2004-12-14 Warner Lambert Co Preparacion de quinazolinas substituidas
CA2527017A1 (en) 2003-05-27 2004-12-09 Pfizer Products Inc. Quinazolines and pyrido [3,4-d] pyrimidines as receptor tyrosine kinase inhibitors
US7501427B2 (en) * 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
ES2399427T3 (es) 2003-08-14 2013-04-01 Array Biopharma, Inc. Análogos de quinazolina como inhibidores de los receptores de la tirosina-quinasa
RU2328287C2 (ru) 2003-08-18 2008-07-10 Пфайзер Продактс Инк. Схема приема erbb2 противоопухолевых агентов
WO2005044302A1 (en) 2003-11-06 2005-05-19 Pfizer Products Inc. Selective erbb2 inhibitor/anti-erbb antibody combinations in the treatment of cancer
KR100735639B1 (ko) 2004-12-29 2007-07-04 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
PT2090575E (pt) 2005-11-15 2011-06-06 Array Biopharma Inc Inibidores de erbb

Also Published As

Publication number Publication date
EP1660090A4 (en) 2008-12-03
CN102432552A (zh) 2012-05-02
US7452895B2 (en) 2008-11-18
KR20060064630A (ko) 2006-06-13
KR20100018079A (ko) 2010-02-16
CA2535614A1 (en) 2005-02-24
CN102432552B (zh) 2016-01-20
NZ545459A (en) 2009-12-24
HK1085400A1 (en) 2006-08-25
BRPI0413565B1 (pt) 2019-10-01
IL173593A0 (en) 2006-07-05
NO20061171L (no) 2006-04-10
EP1660090A1 (en) 2006-05-31
US20050043334A1 (en) 2005-02-24
CN103772373A (zh) 2014-05-07
AU2004264937A1 (en) 2005-02-24
CN103772373B (zh) 2017-06-09
CN103664802A (zh) 2014-03-26
NO336275B1 (no) 2015-07-06
TWI353982B (en) 2011-12-11
RU2006103493A (ru) 2007-09-20
US20090048279A1 (en) 2009-02-19
BRPI0413565B8 (pt) 2021-05-25
WO2005016346A1 (en) 2005-02-24
ES2399427T3 (es) 2013-04-01
DK1660090T3 (da) 2012-12-17
US8278314B2 (en) 2012-10-02
IS8288A (is) 2006-02-07
JP2007502295A (ja) 2007-02-08
CL2004002066A1 (es) 2005-06-03
CY1113992T1 (el) 2016-07-27
PT1660090E (pt) 2013-01-11
EP1660090B1 (en) 2012-11-21
CA2535614C (en) 2009-12-22
KR101028952B1 (ko) 2011-04-12
CN103664802B (zh) 2015-08-05
TW200519096A (en) 2005-06-16
IL173593A (en) 2011-11-30
JP4828421B2 (ja) 2011-11-30
MXPA06001767A (es) 2006-05-12
AU2004264937B2 (en) 2010-04-29
RU2350605C2 (ru) 2009-03-27
KR100953246B1 (ko) 2010-04-16
AR045378A1 (es) 2005-10-26
PL1660090T3 (pl) 2013-04-30

Similar Documents

Publication Publication Date Title
BRPI0413565A (pt) análogos de quinazolina como inibidores de receptor de tirosina quinase
CR7643A (es) Derivados de 1-heterociclialquil -3-sulfonilazaindol o azaindazol como ligandos de 5-hidroxitriptamina-6
ECSP055536A (es) Derivados de 1-heterociclilalquil-3-sulfonilindol o indazol como ligandos de 5-hidroxitriptamina-6
EA201070618A1 (ru) 4-пиразолил-n-арилпиримидин-2-амины и 4-пиразолил-n-гетероарилпиримидин-2-амины в качестве ингибиторов киназ janus
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
EA200501504A1 (ru) Лиганды каннабиноидных рецепторов и их применение
EA200500721A1 (ru) Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств
ATE384061T1 (de) Imidazo- und thiazolopyridine als jak3-kinase- inhibitoren
EA200970402A1 (ru) Триазолопиридазиновые модуляторы протеинкиназ
EA200600677A1 (ru) 5,7-диаминопиразоло[4,3-d]пиримидины c ингибирующей pde-5 активностью
ECSP056072A (es) Pirimidinonas sustituidas
ATE478861T1 (de) Multizyklische verbindung und verwendungsverfahren
EA200870415A1 (ru) Хиназолины для ингибирования pdk 1
EA200901488A1 (ru) Замещенные имидазолопиридазины, как ингибиторы липидкиназы
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
BR0215151A (pt) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
ECSP078062A (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
ECSP045473A (es) Derivados de 1-(aminoalquil)-3-sulfonilindol y 1-aminoalquil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
BR0213094A (pt) Derivados de cromano como ligandos de 5-hidroxi-triptamina-6
ECSP034811A (es) Derivados heterocicliloxi-, -tioxi - y - aminobenzazole tales como ligandos 5-hidroxitriptamina-6
ECSP045156A (es) Derivados de indolilalquilamina como ligandos 5-hidroxitriptamina-6
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
BRPI0412809A (pt) compostos de sulfonildihidrobenzimidazolona como ligantes a 5-hidróxitriptamina-6
YU75603A (sh) Dihidropirimidinska jedinjenja koja su supstituisana na cijano grupi i njihova upotreba u lečenju oboljenja

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/51, 31/517, 31/535; C07D 403/00, 239/82; A61P 35/00

Ipc: A61K 31/51 (2011.01), A61K 31/517 (2011.01), A61K

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/10/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/10/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/08/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF